ATYR (aTyr Pharma) Quality Rank


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.59
GF Value $0.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

aTyr Pharma Quality Rank Related Terms

ATYR
14GF Score
aTyr Pharma Inc ATYR
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.59 is trading 29.1% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Modestly Overvalued.

Key valuation signals for ATYR:

  • Quality Rank:
  • GF Value™: $0.46 vs. price of $0.59 (29.1% above fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.46
GF Value